{"doi":"10.2215/cjn.0000000750","title":"GLP-1 Receptor Agonist Outcomes, Safety, and Body Mass Index Change in a National Cohort of Patients on Dialysis","abstract":"Key Points GLP-1 receptor agonists (GLP-1 RAs) in diabetes and dialysis are associated with 23% lower mortality and 66% higher chance of transplant waitlisting. GLP-1 RAs are not associated with increased risk of acute pancreatitis, biliary complications, or medullary thyroid cancer. GLP-1 RAs are associated with a 32% increased risk of diabetic retinopathy in patients with diabetes on dialysis. Background Of the 808,000 US patients on dialysis, 60% have diabetes and are eligible for glucagon-like peptide-1 receptor agonists (GLP-1 RAs). Safety and outcomes in this population are unknown. We sought to examine GLP-1 RA real-world safety, efficacy, and weight loss in people with diabetes on dialysis. Methods In this observational national cohort study (2013–2021), we identified adults with type 2 diabetes on dialysis. The exposure of interest was GLP-1 RA use. Body mass index (BMI) change after dialysis initiation was quantified among patients with two measurements ( N =6474). Extended Cox models with inverse probability of treatment weights (censoring for kidney transplant waitlisting) were used to quantify all-cause mortality associated with GLP-1 RAs. Specific safety outcomes (acute pancreatitis, biliary complications, medullary thyroid cancer, and diabetic retinopathy) were assessed. Results The study included 151,649 patients on incident dialysis with type 2 diabetes. Mean BMI and weight change among GLP-1 RA users were greater than those among nonusers (−1.47 versus −0.61 kg/m 2 ; −4.03 versus −1.47 kg; P < 0.001 for both). The mortality incidence rate was lower among GLP-1 RA users (219.0 versus 279.5 patients/1000 person-years; P < 0.001). GLP-1 RA use was associated with a 23% lower risk of mortality (adjusted hazard ratio [aHR], 0.77; 95% confidence interval [CI], 0.70 to 0.85; P < 0.001); results were consistent among initiates with BMI ≥30 kg/m 2 . GLP-1 RA use was associated with a 66% higher chance of waitlisting (aHR, 1.66; 95% CI, 1.28 to 2.13; P < 0.001). There was an increased association with diabetic retinopathy (aHR, 1.32; 95% CI, 1.12 to 1.56; P = 0.001), but not with any other safety outcomes. Inferences were consistent across multiple sensitivity analyses. Conclusions GLP-1 RA use in patients with type 2 diabetes on dialysis was associated with weight loss, reduced mortality risk, and increased likelihood of kidney transplant waitlisting. These real-world data are the strongest evidence to date supporting GLP-1 RA use in this population.","journal":"Clinical Journal of the American Society of Nephrology","year":2025,"id":509592,"datarank":0.0,"base_score":0.0,"endowment":0.0,"self_citation_contribution":0.0,"citation_network_contribution":0.0,"self_endowment_contribution":0.0,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":30,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":0,"is_dataset":false,"is_dataset_confidence":0.955,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":"2025-01-01","fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1363789,"name":"Yusi Chen","orcid":"0000-0001-6968-4664","position":1,"is_corresponding":false},{"id":1153672,"name":"Yiting Li","orcid":"0000-0001-6279-5740","position":2,"is_corresponding":false},{"id":225665,"name":"David M. Charytan","orcid":"0000-0002-7695-3583","position":3,"is_corresponding":false},{"id":270991,"name":"Krista L. Lentine","orcid":"0000-0002-9423-4849","position":4,"is_corresponding":false},{"id":883455,"name":"Brian P. Lee","orcid":"0000-0003-2108-1287","position":5,"is_corresponding":false},{"id":1298151,"name":"Nicole Ali","orcid":"0000-0003-1209-2873","position":6,"is_corresponding":false},{"id":1139048,"name":"Mario P. DeMarco","orcid":"0000-0002-3269-0996","position":7,"is_corresponding":false},{"id":1059231,"name":"Michael A. Weintraub","orcid":"0000-0001-9599-9184","position":8,"is_corresponding":false},{"id":429918,"name":"Sunjae Bae","orcid":"0000-0003-0098-8816","position":9,"is_corresponding":false},{"id":1230416,"name":"Bonnie E. Lonze","orcid":"0000-0002-0973-1657","position":10,"is_corresponding":false},{"id":1273079,"name":"Christine Ren‐Fielding","orcid":"0000-0002-2125-5382","position":11,"is_corresponding":false},{"id":979943,"name":"Holly Lofton","orcid":"0000-0002-3403-882X","position":12,"is_corresponding":false},{"id":971353,"name":"Akash Gujral","orcid":"0000-0003-4250-9086","position":13,"is_corresponding":false},{"id":257567,"name":"Dorry L. Segev","orcid":"0000-0002-1924-4801","position":14,"is_corresponding":false},{"id":257566,"name":"Mara McAdams‐DeMarco","orcid":"0000-0003-3013-925X","position":15,"is_corresponding":false},{"id":181731,"name":"Babak Orandi","orcid":"0000-0001-6026-7135","position":0,"is_corresponding":true}],"reference_count":73,"raw_metadata":null,"created_at":"2026-07-19T02:47:24.513904Z","pmid":"40526425","pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}